Methylliberine

Last updated
Methylliberine
Methylliberine.svg
Names
Preferred IUPAC name
2-Methoxy-1,7,9-trimethyl-7,9-dihydro-1H-purine-6,8-dione
Other names
O(2),1,7,9-Tetramethylurate; Tetramethyluric acid; Dynamine
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C9H12N4O3/c1-11-5-6(12(2)9(11)15)10-8(16-4)13(3)7(5)14/h1-4H3
    Key: ZVQXCXPGLSBNCX-UHFFFAOYSA-N
  • InChI=1/C9H12N4O3/c1-11-5-6(12(2)9(11)15)10-8(16-4)13(3)7(5)14/h1-4H3
    Key: ZVQXCXPGLSBNCX-UHFFFAOYAY
  • CN1C2=C(N=C(N(C2=O)C)OC)N(C1=O)C
Properties
C9H12N4O3
Molar mass 224.22 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Methylliberine is an isolate of coffee beans, tea, cola nuts, guarana, cocoa, and yerba mate. [1] It is structurally related to Liberine.

Contents

Pharmacology

Pharmacodynamics

Based on its structural similarity to caffeine and theacrine methylliberine is widely believed to be an adenosine receptor antagonist, although as of 2023 no scientific studies have been done to confirm this action. [2] There is no evidence that methylliberine augments dopamine receptors in a way that is distinct from caffeine, contrary to claims made by manufacturer. [3] [4]

Pharmacokinetics

Methylliberine has a short half-life of only 1.5 hours compared to the 5-7 hour half life of caffeine. [5] An interaction study showed concomitant administration of both caffeine and methylliberine increases the half-life of caffeine by about 2 fold. [5] This is likely due to inhibition of the CYP1A2 enzyme. [5] Safety studies of methyliberine have been conducted in rats. [6]

Related Research Articles

<span class="mw-page-title-main">Caffeine</span> Central nervous system stimulant

Caffeine is a central nervous system (CNS) stimulant of the methylxanthine class. It is mainly used as a eugeroic (wakefulness promoter) or as a mild cognitive enhancer to increase alertness and attentional performance. Caffeine acts by blocking binding of adenosine to the adenosine A1 receptor, which enhances release of the neurotransmitter acetylcholine. Caffeine has a three-dimensional structure similar to that of adenosine, which allows it to bind and block its receptors. Caffeine also increases cyclic AMP levels through nonselective inhibition of phosphodiesterase.

<span class="mw-page-title-main">Phencyclidine</span> Dissociative hallucinogenic drug, mostly used recreationally

Phencyclidine or phenylcyclohexyl piperidine (PCP), also known in its use as a street drug as angel dust among other names, is a dissociative anesthetic mainly used recreationally for its significant mind-altering effects. PCP may cause hallucinations, distorted perceptions of sounds, and violent behavior. As a recreational drug, it is typically smoked, but may be taken by mouth, snorted, or injected. It may also be mixed with cannabis or tobacco.

<span class="mw-page-title-main">Adenosine receptor</span> Class of four receptor proteins to the molecule adenosine

The adenosine receptors (or P1 receptors) are a class of purinergic G protein-coupled receptors with adenosine as the endogenous ligand. There are four known types of adenosine receptors in humans: A1, A2A, A2B and A3; each is encoded by a different gene.

<span class="mw-page-title-main">Caffeine dependence</span> Medical condition

Caffeine dependence is a condition characterized by a set of criteria, including tolerance, withdrawal symptoms, persistent desire or unsuccessful efforts to control use, and continued use despite knowledge of adverse consequences attributed to caffeine. It can appear in physical dependence or psychological dependence, or both. Caffeine is one of the most common additives in many consumer products, including pills and beverages such as caffeinated alcoholic beverages, energy drinks, pain reliever medications, and colas. Caffeine is found naturally in various plants such as coffee and tea. Studies have found that 89 percent of adults in the U.S. consume on average 200 mg of caffeine daily. One area of concern that has been presented is the relationship between pregnancy and caffeine consumption. Repeated caffeine doses of 100 mg appeared to result in smaller size at birth in newborns. When looking at birth weight however, caffeine consumption did not appear to make an impact.

<span class="mw-page-title-main">Theanine</span> Amino acid

Theanine, commonly known as L-theanine and sometimes L-gamma-glutamylethylamide or N5-ethyl-L-glutamine, is an amino acid analogue of the proteinogenic amino acids L-glutamate and L-glutamine and is found primarily in particular plant and fungal species. It was discovered as a constituent of green tea in 1949 and isolated from gyokuro leaves in 1950, thus rendering it a natural product. It constitutes about 1–2% of the dry weight of green tea leaves.

<span class="mw-page-title-main">Paraxanthine</span> Chemical compound

Paraxanthine, also known as 1,7-dimethylxanthine, is a metabolite of theophylline and theobromine, two well-known stimulants found in coffee, tea, and chocolate mainly in the form of caffeine. It is a member of the xanthine family of alkaloids, which includes theophylline, theobromine and caffeine.

<span class="mw-page-title-main">Dopamine agonist</span> Compound that activates dopamine receptors

A dopamine agonist is a compound that activates dopamine receptors. There are two families of dopamine receptors, D1-like and D2-like. They are all G protein-coupled receptors. D1- and D5-receptors belong to the D1-like family and the D2-like family includes D2, D3 and D4 receptors. Dopamine agonists are primarily used in the treatment of the motor symptoms of Parkinson's disease, and to a lesser extent, in hyperprolactinemia and restless legs syndrome. They are also used off-label in the treatment of clinical depression. Impulse control disorders are associated with the use of dopamine agonists for whatever condition.

<span class="mw-page-title-main">Fencamfamin</span> Chemical compound

Fencamfamin (INN), also known as fencamfamine or by the brand names Glucoenergan and Reactivan, is a stimulant which was developed by Merck in the 1960s.

<span class="mw-page-title-main">MMDA-2</span> Psychedelic drug

MMDA-2 (2-methoxy-4,5-methylenedioxyamphetamine) is a psychedelic drug of the amphetamine class. It is closely related to MMDA and MDA.

<span class="mw-page-title-main">Metitepine</span> Chemical compound

Metitepine, also known as methiothepin, is a drug described as a "psychotropic agent" of the tricyclic group which was never marketed. It acts as a non-selective antagonist of serotonin, dopamine, and adrenergic receptors and has antipsychotic properties.

<span class="mw-page-title-main">Cholecystokinin B receptor</span> Protein-coding gene in the species Homo sapiens

The cholecystokinin B receptor also known as CCKBR or CCK2 is a protein that in humans is encoded by the CCKBR gene.

<span class="mw-page-title-main">Eseroline</span> Opioid analgesic compound

Eseroline is a drug which acts as an opioid agonist. It is a metabolite of the acetylcholinesterase inhibitor physostigmine but unlike physostigmine, the acetylcholinesterase inhibition produced by eseroline is weak and easily reversible, and it produces fairly potent analgesic effects mediated through the μ-opioid receptor. This mixture of activities gives eseroline an unusual pharmacological profile, although its uses are limited by side effects such as respiratory depression and neurotoxicity.

<span class="mw-page-title-main">Benocyclidine</span> Chemical compound

Benocyclidine, also known as benzo​thiophenyl​cyclo​hexylpiperidine (BTCP), is a psychoactive recreational drug of the arylcyclohexylamine class which is related to phencyclidine (PCP). It was first described in a patent application naming Marc Caron and colleagues at Duke University in 1997.

Jane Stewart is a Canadian neuroscientist who has been active in the fields of psychology, psychiatry, and psychopharmacology. She is a professor emerita at Concordia University in Montreal, Canada.

<span class="mw-page-title-main">Arylcyclohexylamine</span> Class of chemical compounds

Arylcyclohexylamines, also known as arylcyclohexamines or arylcyclohexanamines, are a chemical class of pharmaceutical, designer, and experimental drugs.

<span class="mw-page-title-main">Melanocyte-inhibiting factor</span> Chemical compound

Melanocyte-inhibiting factor (also known as Pro-Leu-Gly-NH2, Melanostatin, MSH release–inhibiting hormone or MIF-1) is an endogenous peptide fragment derived from cleavage of the hormone oxytocin, but having generally different actions in the body. MIF-1 produces multiple effects, both blocking the effects of opioid receptor activation, while at the same time acting as a positive allosteric modulator of the D2 and D4 dopamine receptor subtypes, as well as inhibiting release of other neuropeptides such as alpha-MSH, and potentiating melatonin activity.

<span class="mw-page-title-main">Theacrine</span> Chemical compound

Theacrine, also known as 1,3,7,9-tetramethyluric acid, is a purine alkaloid found in Cupuaçu and in a Chinese tea known as kucha. It shows anti-inflammatory and analgesic effects and appears to affect adenosine signalling in a manner similar to caffeine. In kucha leaves, theacrine is synthesized from caffeine in what is thought to be a three-step pathway. Theacrine and caffeine are structurally similar.

<span class="mw-page-title-main">5-Chloro-αMT</span> Chemical compound

5-Chloro-α-methyltryptamine (5-Chloro-αMT), also known as PAL-542, is a tryptamine derivative related to α-methyltryptamine (αMT) and one of only a few known specific serotonin-dopamine releasing agents (SDRAs). It has been investigated in animals as a potential treatment for cocaine dependence. The EC50 values of 5-chloro-αMT in evoking the in vitro release of serotonin (5-HT), dopamine (DA), and norepinephrine (NE) in rat synaptosomes were reported as 16 nM, 54 nM, and 3434 nM, with an NE/DA ratio of 63.6 and a DA/5-HT ratio of 3.38, indicating that it is a highly specific and well-balanced SDRA. However, 5-chloro-αMT has also been found to act as a potent full agonist of the 5-HT2A receptor, with an EC50 value of 6.27 nM and an efficacy of 105%. It is likely to act as a potent agonist of other serotonin receptors as well.

<span class="mw-page-title-main">Sheena Josselyn</span> Canadian neuroscientist

Sheena Josselyn is a Canadian neuroscientist and a full professor of psychology and physiology at Hospital for Sick Children and The University of Toronto. Josselyn studies the neural basis of memory, specifically how the brain forms and stores memories in rodent models. She has made critical contributions to the field of Neuronal Memory Allocation and the study of engrams.

<span class="mw-page-title-main">Bromerguride</span> Medication

Bromerguride, also known as 2-bromolisuride, is an antidopaminergic and serotonergic agent of the ergoline group which was described as having atypical antipsychotic properties but was never marketed. It was the first antidopaminergic ergoline derivative to be discovered. The pharmacodynamic actions of bromerguride are said to be "reversed" relative to its parent compound lisuride, a dopaminergic agent.

References

  1. "Minor alkaloids in caffeine-containing beverages". Deutsche Lebensmittel-Rundschau. 96 (11): 363–368. 2000. Archived from the original on 2014-12-10. Retrieved 2013-10-16.
  2. VanDusseldorp, Trisha A.; Stratton, Matthew T.; Bailly, Alyssa R.; Holmes, Alyssa J.; Alesi, Michaela G.; Feito, Yuri; Mangine, Gerald T.; Hester, Garrett M.; Esmat, Tiffany A.; Barcala, Megan; Tuggle, Karleena R.; Snyder, Michael; Modjeski, Andrew S. (28 February 2020). "Safety of Short-Term Supplementation with Methylliberine (Dynamine®) Alone and in Combination with TeaCrine® in Young Adults". Nutrients. 12 (3): 654. doi: 10.3390/nu12030654 . PMC   7146520 . PMID   32121218.
  3. Garrett, B. E.; Holtzman, S. G. (January 1994). "D1 and D2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats". Pharmacology, Biochemistry, and Behavior. 47 (1): 89–94. doi:10.1016/0091-3057(94)90115-5. ISSN   0091-3057. PMID   7906891. S2CID   23508010.
  4. VanDusseldorp, Trisha A.; Stratton, Matthew T.; Bailly, Alyssa R.; Holmes, Alyssa J.; Alesi, Michaela G.; Feito, Yuri; Mangine, Gerald T.; Hester, Garrett M.; Esmat, Tiffany A.; Barcala, Megan; Tuggle, Karleena R.; Snyder, Michael; Modjeski, Andrew S. (2020-02-28). "Safety of Short-Term Supplementation with Methylliberine (Dynamine®) Alone and in Combination with TeaCrine® in Young Adults". Nutrients. 12 (3): 654. doi: 10.3390/nu12030654 . ISSN   2072-6643. PMC   7146520 . PMID   32121218.
  5. 1 2 3 Mondal, Goutam; Wang, Yan-Hong; Yates, Ryan; Bloomer, Richard; Butawan, Matthew (9 August 2022). "Caffeine and Methylliberine: A Human Pharmacokinetic Interaction Study: Original Research". Journal of Exercise and Nutrition. 5 (3). doi: 10.53520/jen2022.103124 .
  6. Murbach, Timothy S.; Glávits, Róbert; Endres, John R.; Clewell, Amy E.; Hirka, Gábor; Vértesi, Adél; Béres, Erzsébet; Szakonyiné, Ilona Pasics (27 October 2019). "A Toxicological Evaluation of Methylliberine (Dynamine®)". Journal of Toxicology. 2019: 1–25. doi: 10.1155/2019/4981420 . PMC   6930730 . PMID   31911801.